Published in final edited form as:

J Org Chem. 2009 November 6; 74(21): 8232–8242. doi:10.1021/jo901725k.

5(6)-*anti*-Substituted-2-azabicyclo[2.1.1]hexanes. A Nucleophilic Displacement Route

Grant R. Krow^{*,†}, Ram Edupuganti[†], Deepa Gandla[†], Amit Choudhary[§], Guoliang Lin[†], Philip E. Sonnet[†], Charles DeBrosse[†], Charles W. Ross III^d, Kevin C. Cannon[¶], and Ronald T. Raines[‡]

Department of Chemistry, Temple University, Philadelphia, Pennsylvania 19122, Graduate Program in Biophysics and Departments of Biochemistry and Chemistry, University of Wisconsin, Madison, Wisconsin 53706, Department of Chemistry, Penn State Abington, Abington, Pennsylvania 19104, and Department of Medicinal Chemistry, Merck Research Laboratories, Merck & Co., Inc., West Point, Pennsylvania 19486-004

Abstract

Nucleophilic displacements of 5(6)-*anti*-bromo substituents in 2-azabicyclo[2.1.1]hexanes (methanopyrrolidines) have been accomplished. These displacements have produced 5-*anti*-X-6-*anti*-Y-difunctionalized-2-azabicyclo[2.1.1]hexanes containing bromo, fluoro, acetoxy, hydroxy, azido, imidazole, thiophenyl, and iodo substituents. Such displacements of *anti*-bromide ions require an amine nitrogen and are a function of the solvent and the choice of metal salt. Reaction rates were faster and product yields were higher in DMSO when compared to DMF and with CsOAc compared to NaOAc. Sodium or lithium salts gave products, except with NaF, where silver fluoride in nitromethane was best for substitution by fluoride. The presence of electron-withdrawing F, OAc, N₃, Br, or SPh substituents in the 6-*anti*-position slows bromide displacements at the 5-*anti*-position.

Introduction

Pyrrolidines **1**, especially those with hydroxy,¹ amino,² fluoro,³ or thio⁴ substituents in a 1,2-relationship β to the nitrogen atom, are a valuable source of biologically significant

^{*}To whom correspondence should be addressed. Grkrow@temple.edu.

[†]Department of Chemistry, Temple University

[§]Department of Medicinal Chemistry, Merck Research Laboratories

[¶]Graduate Program in Biophysics, University of Wisconsin–Madison

^dPenn State Abington

[‡]Departments of Chemistry and Biochemistry, University of Wisconsin–Madison

Supporting Information Available: General experimental procedures; control reactions with dibromide **13**; reactions in DMSO to prepare **16a**, **18**, **19**, **20**, **24a**, **27**, **32a**, and **34**; reaction with BAST to prepare **26** and attempted preparation of **26** using AgF/DMF; variance of PhSNa concentrations (Table S-5) with monobromide **10** to give thioether **30**; comparison of reactivities for reaction of bromides **9**, **10**, **11**, **23** with PhSNa (Table 6); proposed mechanisms for formation of aldehyde **19**, X-ray diffraction analysis of dibromide **9**; copies of ¹H NMR, ¹³C NMR, and ¹⁹F NMR for new compounds; a calculated spectrum for *N*-methyl-6-*anti*-fluoro-5-*anti*-hydroxy-2-azabicyclo[2.1.1]hexane **32c**; SCF Energies and coordinates of optimized geometries for amine invertomers of bromides **9**–**11** shown in Table 4 along with pictures of orbitals for dibromide **9**; and energy minimizations of ions derived from *N*-methyl-2-azabicyclo[2.1.1]hexyl-5-cations **39**. This material is available free of charge via the Internet at <http://pubs.acs.org>.

molecules. One strategy in the search for new bioactive molecules is to incorporate key pharmacophoric units into inflexible structures.^{5–7} Viewed in this light methanobridged pyrrolidines **1** (2-azabicyclo[2.1.1]hexanes) that display their functionalities in defined spatial orientations are of interest. Such molecules may prove to be valuable scaffolds for incorporation into proteins,⁸ for drug discovery, or for other purposes.^{3b} To realize this potential there is a need for practical methods to introduce a diverse array of heteroatom substituents onto these structures.⁹

Heteroatoms at C₅(C₆) of *N*-acyl-2-azabicyclo[2.1.1]hexanes have been introduced by rearrangement routes (X = *syn*- or *anti*-halogen, hydroxyl),¹⁰ nucleophilic ring closure of cyclobutanes (X = *syn*-SePh),^{6a} or a thermal 2+2 cycloaddition (X/H = difluoride).¹¹ There are a few examples of *N*-acyl monoheteroatom-substituted *anti*-5-hydroxy-2-azabicyclo[2.1.1]hexanes **2a** (X = OH) formed by reductive dehalogenation of 5-*anti*,6-*anti*-bromohydrins.^{3b,10a,10d}

Recently, we described the preparation of *N*-BOC-5-*syn*- and 5-*anti*-carboxy-2-azabicyclo[2.1.1]hexanes **2e** (R = H, X = COOH), isolated mainly as the *syn*-5-carboxy isomers,¹² and their use for introduction of heteroatom functionality into this ring system.^{2c} The Curtius rearrangement was especially useful for the stereospecific conversion of 5-*syn*- and 5-*anti*-acids to the corresponding 5-*syn*- and 5-*anti*-amines, isolated as their carbamates **2b** [R = H, X = NHCOOBn(Et)]. The major 5-*syn*-carboxylic acid **2e** has been used to introduce other 5-heteroatoms by radical decarboxylative substitutions of either the acid or its Barton ester. Reactions led to mainly 5-*syn*-chloro, 5-*syn*-bromo, 5-*syn*-iodo and 5-*syn*-pyridylthioether substitution products admixed with only minor amounts of the 5-*anti* isomers (0–11%); an exception was the iodide that gave 17–44% 5-*anti*-isomer. Yields were generally poor and this non-stereospecific method is not of general utility as a source of halide or thioether substitution. The rearrangement route remains the most useful for introduction of 5-*anti*-hydroxy and 5-*anti*-bromine groups as in **2a** and **2e**. Thus, methods to displace these substituents by other nucleophiles are welcome.

Nucleophilic substitution reactions of 5-tosylbicyclo[2.1.1]hexanes, the parent carbon bicycle of structures **2**, provide insights into the reactivity of 5-substituents in this strained ring system. The substitution reactions of 5-*syn* substituents occur fairly easily, proceed with retention of configuration, but are accompanied by rearrangement products. The *syn*-5-alcohol **3a** and phosphorus tribromide afforded a product assigned as the 5-*syn*-bromide **3b** (17%) admixed with some 4-bromocyclohexane, while *syn*-5-tosylate **3c** reacts with tetrabutylammonium chloride at 5 °C for 29h to afford a product assigned as 5-*syn*-chloro[2.1.1]hexane **3d** (43%) with retained stereochemistry.^{13a} Both these products are suggestive of neighboring group participation by the neighboring methanobridge.^{13b} On the other hand nucleophilic displacement of 5-*anti*-substituents, our goal, is more difficult. The *syn*-tosylate **3c** reacted at a rate 3×10^6 that of the 5-*anti*-tosylate **4**.^{13b,c} In order to induce a reasonable rate for acetic acid solvolysis of the *anti*-tosylate **4**, a temperature of 164 °C was required. More importantly, none of the products retained the bicyclo[2.1.1]hexane

structure. Acetolysis of **4** produced 4-cyclohexenyl tosylate (80%), 4-cyclohexenyl acetate (8%), and bicyclo[3.1.0]hex-2-yl acetate (8%) as the major products.^{13c}

3a X = OH

3b X = Br

3c X = OTs

3d X = Cl

4 X = OTs

Nevertheless, there are two examples of nucleophilic displacement reactions of 5-*anti*-substituents in *N*-acyl-2-azabicyclo[2.1.1]hexanes by fluoride in which products have been isolated that maintain the integrity of the heterobicyclic structure. The conversion of alcohol **5a** to fluoride **6a** was carried out using bis(2-methoxyethyl)aminosulfur trifluoride [BAST or Deoxo-Fluor] in refluxing methylene chloride (63%) (eq 1).^{3b} Limited success was observed with the replacement of the 5-*anti*-iodo substituent of **5b** by fluoride using AgF/nitromethane at 80 °C/4h to give **6b** (19%) (eq 2).^{2c} Retention of stereochemistry was observed in both cases of displacement reactions of C₅-*anti*-substituents. We have not been successful in nucleophilic displacements of 5-*anti*-bromo substituents in *N*-acyl-5-*anti*-bromo-2-azabicyclo[2.1.1]hexanes. (See supplemental material.)

eq 1

It occurred to us that replacement of the *N*-acyl substituent by an *N*-alkyl group might facilitate nucleophilic substitution reactions. Malpass and White¹⁴ have shown that a free amine can facilitate displacements in a normally slow reacting 7-norbornyl position.¹³ The 7-bromo group in *N*-benzyl-*anti*-7-bromo-2-azabicyclo[2.2.1]heptane **7** was displaced by various nucleophiles at 100–110 °C in DMF to give products **8**. Only products with retained stereochemistry were observed, presumably the result of neighboring group participation.¹⁴

eq 2

The key objective of this work was to see if replacement of *N*-acyl groups by *N*-benzyl in readily available 5-*anti*-bromo- and 5-*anti*-,6-*anti*-dibromo-2-azabicyclo[2.1.1]hexanes would allow for displacement of the bromine atom by useful heteroatom nucleophiles.¹⁵ Specifically, dibromide **9**, monobromide **10**, and fluorobromide **11** have been chosen as substrates. We now describe conditions that enable preparation of 5(6)-*anti*-substituted-2-azabicyclo[2.1.1]hexanes with halogen, nitrogen, sulfur, and oxygen containing groups X starting from these bromides. Since preparation of 5-*anti*-bromides with compatible substituents at other ring positions is feasible,^{3b,9,10} the functional group modifications described for these bromides should prove useful in the preparation of more highly functionalized 5(6)-substituted-2-azabicyclo[2.1.1]hexanes **2**. Some of these structures can be precursors of methanoproline **2** (R = COOH);^{3b,16} we especially desired to prepare novel 5,6-dihydroxy-, 5,6-difluoro-, 5,6-diamino-, and mixed 5,6-hydroxyfluorides that are not available by other synthetic routes.^{7b}

Results and Discussion

The requisite *N*-benzyl dibromides **9–11** were prepared from the *N*-alkoxycarbonyl dihydropyridine photoproduct **12** (Scheme 1).^{7b} The known dibromide **13**^{7b} was selectively monobrominated using (TMS)₃SiH/toluene/70 °C to give monobromide **14** (74%). Conversion of alkene **12** to bromofluoride **15** (53%) was carried out using NBS/nitromethane/Et₃N·3HF.¹⁷ Hydrogenolysis of the carbobenzyloxy protecting groups of **13–15** with H₂/Pd(OH)₂/MeOH and subsequent benzylation with benzyl bromide/Et₃N/CH₃CN afforded the *N*-benzyl compounds **9–11** in 51–69% overall yields for the two steps.

Our first attempts to effect nucleophilic displacements of dibromide **9** (Scheme 2) were carried out in DMF under conditions used successfully by Malpass¹⁴ for halide displacements with bromide **5** (R = Bn, Y = H). The results are shown in Table 1. Dibromide **9** was slowly converted to its diacetate **16a** using excess cesium acetate¹⁸ (entry 1). But, displacement of the second bromine was difficult. Even after 5 days there was unreacted starting material and a large amount of bromoacetate **17** in the reaction mixture. For the stereochemical assignment of diacetate **16**, the protons H₅/H₆ are identical and appear as a singlet in the ¹H NMR spectrum. The retained 5-*anti*-6-*anti* stereochemistry is apparent from the absence of coupling between H₁ or H₄ and their vicinal *syn* protons H₅/H₆. In this ring system these *syn* protons characteristically do not show vicinal coupling.^{2c} For bromoacetate **18**, there is the characteristic W-plan coupling between the *syn* protons H₅ and H₆ (*J* = 7.2 Hz).^{7b} Methanolysis of the diacetate **16a** afforded diol **16b**. Attempted preparation of difluoride **18** from dibromide **9** using AgF/DMF formed instead the pyrrole aldehyde **19** (entry 2).¹⁹

In order to introduce nitrogen functionality bromide **9** was reacted with sodium azide in DMF (entry 3) to give diazide **20** and azidobromide **21**. As noted with CsOAc (entry 1), it was difficult to replace the second bromine in azidobromide **21** despite extended reaction times (8d). The symmetrical diazide **20** gave a singlet for H₅/H₆ while bromoazide **21** showed the characteristic W-plan coupling for H₅/H₆ indicating that both structures have 5-*anti*,6-*anti* stereochemistry. The long reaction times and low yields in DMF solvent for preparation of desired diacetate **16a** and diazide **20**, along with the failure to prepare the desired difluoro isomer **18**, initiated a search for alternative superior reaction conditions.

Dimethylsulfoxide was found to be a superior solvent for nucleophilic displacement reactions of dibromide **9** (entry 4).²⁰ The substitution of DMSO for DMF, and otherwise the same reaction conditions in entry 1 for the reaction with CsOAc, resulted in complete conversion to the diacetate **16a** in a suitable yield after 5 days. The use of cesium acetate was clearly superior to sodium acetate in this reaction (entry 5). Our pleasure was tempered

somewhat by the failure of DMSO as solvent to enable dibromide **9** to be converted to a desired difluoride **18** in the presence of NaF (entry 6); again only the pyrrole aldehyde **19** was obtained. But, it was discovered that difluoride **18** could be obtained in small yield (24%) by reaction of diol **16b** with BAST (entry 7).^{3b} The symmetrical difluoride evidenced the expected multiplet AA'XX' pattern in the ¹H NMR spectrum shown in Figure 1. The main product in the reaction was the oxidized ring cleaved pyrrole aldehyde **19**. Later, it was found that the difluoride **18** could be made directly from the dibromide **9** in better yield by reaction with silver fluoride in nitromethane as solvent (entry 8).

The symmetrical diazide **20** also was prepared from dibromide **9** in both vastly improved yield (87%) and in shorter time (2 days) simply by replacing DMF with DMSO solvent (entry 9). With DMSO solvent it was also possible to prepare the symmetrical thiophenyl ether **22**, although after 5h some bromothiophenyl ether **23** and unreacted dibromide **9** remained (entry 10).

Reactions of monobromides **10** and **11**

We next turned our attention to the monobromide **10** (Scheme 3). Its substitution reactions are tabulated in Table 2. Our initial efforts again focused upon reactions in DMF solvent because of precedent.¹⁴ With silver acetate in DMF bromide **10** gave acetate **24a** in moderate yield (entry 1). This was methanolized using K₂CO₃/methanol to give alcohol **24b** (84%). To show that the benzyl group could be removed without destruction of the strained ring, alcohol **24** was hydrogenolyzed and the resulting amine was protected by reaction with (BOC)₂O to give *N*-BOC alcohol **25** (92%).

Monobromide **10** and AgF in DMF gave the same ring-opened and oxidized pyrrole aldehyde **19** (entry 2) observed upon reaction of dibromide **9** under these conditions. Bromide **10** in DMF did not react with NaF (entry 3), but it did react with NaN₃ and gave azide **27** in moderate yield (entry 4). The azide **27** was reduced using triphenylphosphine/water and the resultant amine was reacted with (BOC)₂O to afford the protected carbamate **28**. An *N*-imidazole ring could be introduced by generation of lithium imidazole in DMF and reaction with bromide **10** to give amine **29** (entry 5). Sodium iodide (3 equiv) effected partial displacement of bromide ion to give an inseparable 50:50 mixture of bromide **10** and iodide **31** (entry 6).

DMSO again proved to be a superior solvent for the replacement of bromide using cesium acetate (entry 7), and bromide **10** produced acetate **24a** in high yield. Cesium acetate was found to be a better salt for the displacement than NaOAc. NaF in DMSO did not yield a fluoride with bromide **10** (entry 8). The desired fluoride **26** could be obtained from alcohol **24b** upon reaction with BAST (entry 9), but the fluoride **26** was obtained in higher yield from bromide **10** using AgF in nitromethane (entry 10). DMSO was shown to be a better solvent for bromide **10** in its reactions with NaN₃ to give the azide **27** (entry 11) or with NaSPh to give the thiophenyl ether **30** (entry 12). It was possible to convert the bromide **10** to the iodide **31** using excess NaI/acetone after extended reflux (entry 13). ¹H NMR indicated complete conversion of the bromide. The 5-*anti* stereochemistry for all new compounds in Table 2 was indicated by the observation of W-plan ¹H NMR couplings (*J*_{5,6} = 6.9–7.6 Hz).

The next substrate investigated was the bromofluoride **11** (Scheme 4) and its reactions are tabulated in Table 3. The bromofluoride **11** reacted slowly with CsOAc in DMF to give fluoroacetate **32a** (entry 1). A sequence of methanolysis of the acetate **32a** to alcohol **32b**, then hydrogenolysis followed by acylation with (BOC)₂O, gave a desired fluoroalcohol **33** (86%). Formation of azide **34** from bromofluoride **11** was also a slow reaction (entry 2) and

was accompanied by decomposition. The azide **34** was converted to the amine **35** using triphenylphosphine/water and the amine was acylated to give the acetamide **36**.

While fluoroalcohol **32b** showed coupling between OH-F ($J = 3.9$ Hz),²¹ there was no evidence for such coupling in either the fluorine or proton NMR spectra of amine **35** or amide **36**. Molecular models indicate the 5-*anti* and 6-*anti* substituents are not actually parallel, but point slightly away from each other. The 5-*anti*,6-*anti* arrangement of halogen substituents was again indicated by W-plan couplings ($J_{5,6} = 7.1$ – 7.8 Hz).

Replacement of solvent DMF by DMSO facilitated the displacement reactions of **11** to give fluoroacetate **32a** with either NaOAc (entry 3) or more effectively with CsOAc (entry 4). The same solvent effect was observed in the improved yields in formation of azide **34** upon reaction of **11** with NaN₃ in DMSO (entry 5). It was also possible to prepare the fluorothioether **37** using NaSPh in DMSO, although the reaction was quite slow (entries 6,7).

The ease of bromide displacements in bromides **9**–**11** was dependent upon the adjacent substituent X. Monitoring of the disappearance of starting bromides indicated a relative reactivity order monobromide **10** > dibromide **9** > fluorobromide **11** (see Supplemental Section). Nucleophilic substitution reactions with the bromide **10** in DMSO solvent with CsOAc or NaN₃ required hours for completion, with the dibromide **9** a few days, and with the fluorobromide **11** five-seven days. In addition, upon displacement of one of the bromides of dibromide **9** by acetate, azide, or thiophenyl it took longer to displace the remaining bromides of bromoacetate **17**, bromoazide **21**, or bromo(phenylthio) ether **23** (Table 1). These reactivity orders indicate that all parallel heteroatom substituents in the adjacent methyl bridge, so far investigated, are rate retarding for bromide substitution.

One plausible explanation for the rate retarding effects of heteroatom groups is that electron withdrawal of the nitrogen lone pair by a second atom X reduces the ability for nitrogen atom interaction with the leaving bromide. In molecular orbital terms the nitrogen's lone pair of electrons could interact with the σ^* orbitals of the C-Br bond. On the basis of the electronegativity of the non-reacting C-X bond ($H < Br < F$), it might be predicted that the $n \rightarrow \sigma^*$ overlap for the reacting C-Br bond should follow the order monobromide **10** > dibromide **9** > fluorobromide **11**. To gain evidence about the substituent effect upon lone pair $n \rightarrow \sigma^*$ interactions, NBO calculations were performed for structures **9**–**11**.^{22,23} The calculations, shown in Table 4, indicate the nitrogen lone pair electrons, front lobe and rear lobe, interact with the σ^* orbitals of *both* C₅ and C₆ substituents. Pictures in Figure 2 show the orbital overlap for the two lobes of the nitrogen lone pair orbital in the dibromide **9**.^{23d} The larger $n \rightarrow \sigma^*$ interaction in each case occurs from the *endo-N*-benzyl conformer with the rear lobe (yellow) of the nitrogen atom overlapping ($N \rightarrow C_5Br$).²⁴ While it is true that the calculated relative overlap stabilization energies (**10** > **9** > **11**) are consistent with the observed reactivity order of (**10** > **9** > **11**) with nucleophiles, the ground state interaction energies are too similar for this factor alone to explain the large relative rate differences. Indeed, the relative stabilization energies may differ appreciably as the corresponding transition state energies are approached. Electron lone pair orbital interactions would be expected to become more important as positive charge is created at C₅.

In order to gain information on charged intermediates derived from *N*-methyl substrates **38a-c** we performed single point energy calculations of *N*-methyl carbocations **39a-c** (Scheme 5) by two different means: (1) Hartree-Fock 6-31+G(d,p)²⁵ and (2) B3LYP/6-31+G(d,p)²⁶ methods/basis sets using the Gaussian 03 suite of computations.²² We then optimized these structures for geometry using the same two methods. In all instances, save one, each optimization of a cation **39** led to an iminium ion **40**; *exo* and *endo* isomers led to

the same ions. The one exception occurred with bromofluoride **38c** using method (2) in which the aziridinium ion **41c** was the outcome of the calculation. Independently, we optimized iminium ion **40c** using method 2. The fluoro aziridinium ion **41c** was calculated to be 43.5 kcal/mol less stable than fluoroiminium ion **40c**. See the supplemental for details on aziridinium ions **41a,b**.²⁷

Considering the large energy preference calculated for the gas phase iminium ions **40** versus the aziridinium ions **41**, it is perhaps surprising that the 5-*anti*-bromo-2-azabicyclo[2.1.1]hexanes **9–11**, related to **38a–c**, can undergo nucleophilic substitutions to afford unrearranged 5(6)-*anti* products related to **42**. A 1,2-alkyl shift of C₆ from C₁ to C₅ on the *anti*-face of a cationic species **39** leads to iminium ion **40**. Unrearranged products **42** that have retained stereochemistry are consistent with an intermediate ion that under suitable conditions is resistant to rearrangement. Such an ion in solution might be an aziridinium ion such as **41**, associated with its counterion.

Solvent effects are consistent with the need to stabilize a transition state leading to charged intermediates, such as **41a–c**. The more polar DMSO was a more effective solvent than DMF for the displacement reactions of all substrates **9–11**.^{20,28} A “cesium ion effect” was also noted for acetate displacements.^{28–30} Reactions of fluorobromide **11** with CsOAc and NaOAc are illustrative. This substrate remained 64% unreacted (Table 4, entry 3) with NaOAc in DMSO solvent at 70 °C after 5 days; but with CsOAc and the same temperature/solvent conditions fluorobromide **11** reacted completely (Table 3, entry 4). These reactions were run under heterogeneous conditions, and thus the salt solutions were concentrated. The greater solubility of CsOAc than NaOAc in DMSO and DMF, as well as lesser ion pairing of cesium salts, increases the ionic strength of the CsOAc reaction solutions and facilitates the formation of charged ions in the polar solvents.³⁰

Silver ions facilitated bromide displacements. The outcomes of the silver salt reactions we investigated were dependent upon counterion and solvent. Illustrative are the conversions of monobromide **10** in Table 2. AgOAc/DMF gave acetate **20a** (entry 1). However, with AgF/DMF the reaction took a different course and an oxidative rearrangement occurred to give pyrrole aldehyde **19** (entry 2). The sodium salt NaF/DMF was unreactive with bromide **10** over 12h (entry 3), but the silver salt AgF/CH₃NO₂ provided fluoride **26** (entry 10).

Reactions of the alcohols **16b** (25 °C) and **24b** (40 °C) with BAST/CH₂Cl₂ to give fluorides **18** and **26** were markedly easier than conversion of bromides **9** (50 °C) or **10** (70 °C) to the fluorides, even with AgF/CH₃NO₂ (Table 1, entries 7,8 and Table 2, entries 10,11). The hydroxyl groups are activated for displacement by BAST after formation of O-sulfur bonds; fluorination reactions occurred in CH₂Cl₂ in a few hours.

The oxidative ring opening reaction to form the aromatic aldehyde **19** occurred under a variety of conditions. Reactions of dibromide **9** in Table 1 are informative. AgF/DMF afforded the aldehyde **19** (entry 1), but so did NaF/DMSO (entry 6). AgF/CH₃NO₂ gave a mixture of difluoride **18** and aldehyde **19** (entry 8). In two trials with NaN₃/DMF similar to entry 3, but using less pure non-crystalline dibromide **9**, a small amount (<6%) of aldehyde **19** was obtained with air as the only recognized oxidant. Aldehyde **19** also formed during reactions of BAST with diol **16b** (Table 1, entry 7). For proposed mechanisms to this oxidized ring-cleaved aldehyde **19**, see the Supplemental Material.

Conclusion

The novel *N*-benzyl-5-*anti*,6-*anti*-dibromo-2-azabicyclo[2.1.1]hexane nitrogen mustard **9**, the bromide **10** and bromofluoride **11** react with nucleophiles to give products with retained

stereochemistry. We have observed single bromide displacement reactions, and somewhat slower displacements of two bromides by appropriate oxygen (acetate), nitrogen (azide, imidazole), thioether (phenylthio), and halide (fluoride, iodide) nucleophiles. The present synthetic route describes the first reported examples of 5-*anti*,6-*anti* diols, difluorides, diazides, dithioethers, fluoroamines, fluorothioethers, as well as the first 5-*anti*-imidazoles. We presently envision use of the diols, fluoroalcohols and difluorides as key intermediates for the preparation of methanoproline derivatives, desired in order to study substituent effects on amide conformations.

Experimental Section

N-Benzyl-5-*anti*,6-*anti*-dibromo-2-azabicyclo[2.1.1]hexane (9)

To a solution of dibromide **13**^{7b} (1000 mg, 2.67 mmol) in methanol (75 mL) there was added Pd(OH)₂ (150 mg). The solution was degassed and stirred under a H₂ filled balloon for 1 h at room temperature. The reaction mixture was filtered through Celite, the filtrate was evaporated and the residue was chromatographed on silica gel (9:1 EtOH/MeOH) to give 513 mg (80%) of dibromoamine **13-int** at *R*_f = 0.58 (2:1 EtOH/MeOH); ¹H NMR (400 MHz, CDCl₃) δ 4.11 (s, 2H, H₅ and H₆), 3.87 (d, *J* = 6.0 Hz, 1H, H₁), 3.35 (br s, 1H, NH), 3.17 (s, 2H, 2H₃), 3.10 (d, *J* = 6.0 Hz, 1H, H₄); ¹³C NMR (100 MHz, CDCl₃, RT) δ 66.2, 52.3, 51.2, 47.1; HRMS *m/z* 239.9014, 241.9001, 243.8983, calcd for C₅H₈N^{79/79, 79/81, 81/81}Br₂ (M+H) 239.9023, 241.9003, 243.8983. To a solution of amine (0.50 g, 2.08 mol) in acetonitrile (20 mL) there was added Et₃N (1.69 g, 16.60 mol) and then BnBr (1.42 g, 8.30 mol) dropwise at room temperature. The reaction mixture was stirred at room temperature for 36 h. Solvent was removed *in vacuo*, ether (75 mL) was added, the mixture was stirred for 10 min at room temperature, then filtered and the residue was washed with ether (25 mL). Solvent again was removed *in vacuo* to afford crude dibromide **9**. This was chromatographed on silica gel (hexanes/ether 4:1) to afford 590 mg (86%) of an off-white solid dibromide **9** at *R*_f = 0.75 (1:1 hexanes/ether); mp 68–70 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.36–7.27 (m, 5H, Ph), 4.32 (s, 2H, H₅ and H₆), 3.85 (s, 2H, CH₂Ph), 3.61 (d, *J* = 6.6 Hz, 1H, H₁), 3.12 (dd, *J* = 6.6, 0.9 Hz, 1H, H₄), 2.92 (s, 2H, 2H₃); ¹³C NMR (100 MHz, CDCl₃) δ 137.8, 128.5, 127.4, 70.1, 58.6, 55.1, 52.4, 51.1; HRMS *m/z* 329.9482, 331.9472, 333.9453, calcd for C₁₂H₁₄N^{79/79, 79/81, 81/81}Br₂ (M+H) 329.9493, 331.9473, 333.9453. Hexanes (0.3 mL) were added to a vial with a syringe that contained about 5 mg of dibromide **9** dissolved in ether (0.2 mL). The vial was wrapped with aluminum foil and small holes were made with a syringe and the solution was allowed to sit for 3 d to give crystals suitable for x-ray crystallography.

N-(Benzyloxycarbonyl)-5-*anti*-bromo-2-azabicyclo[2.1.1]hexane (14)

To a solution of dibromide **13** (693 mg, 1.8 mmol) in toluene (50 mL) was added (TMS)₃SiH (596 μL, 1.9 mmol) and AIBN (40 mg). The resulting solution was allowed to stir at 70 °C for 3 h. The solvent was concentrated *in vacuo* and flash chromatography gave 407 mg (74%) of the monobromide **14** at *R*_f = 0.39 (2:1 hexanes/ether); ¹H NMR (400 MHz, CDCl₃) δ 7.11 (m, 5H), 4.91 (s, 2H), 4.19 (br d, *J* = 6.3 Hz, H₅), 3.58 (d, *J* = 8.4 Hz, H₁), 3.27 (d, *J* = 9.0 Hz, H₃), 3.23 (d, *J* = 9.0 Hz, H₃), 2.79 (dm, *J* = 8.1 Hz, H_{6anti}), 2.67 (br, 1H, H₄), 1.40 (dd, *J* = 8.1, 6.3 Hz, H_{6syn}); ¹³C NMR (100 MHz, CDCl₃) δ 155.5, 136.9, 128.9, 128.5, 128.4, 68.6, 65.2, 55.2, 49.4, 46.3, 39.3 and 25.5; HRMS *m/z* found 296.0284, calcd for C₁₃H₁₄NO₂Br (M+H) 296.0281, *m/z* 318.0105 calcd for C₁₃H₁₃NO₂BrNa (M+Na) 318.0105.

N-Benzyl-5-*anti*-bromo-2-azabicyclo[2.1.1]hexane (10)

To a solution of the monobromide **14** (708 mg, 2.4 mmol) in MeOH (40 mL) was added Pd(OH)₂ (71 mg) and the resulting solution was degassed and allowed to stir for 1 h at RT

under hydrogen. After 1 h the catalyst was filtered via Celite and the solvent was removed *in vacuo* to give 500 mg of the crude amine. Without further purification the amine was dissolved in acetonitrile (20 mL) and to the resulting solution was added Et₃N (405 mg, 4.0 mmol) and BnBr (328 mg, 1.9 mmol). The resultant solution was stirred at RT for 3 days. Solvent was removed *in vacuo* to give an oil which on flash chromatography gave 351 mg (58%) of the bromide **10** at *R_f*=0.40 (1:1 hexane/ether); ¹H NMR (400 MHz, CDCl₃) δ 7.39-7.24 (m, 5H), 4.11 (d, *J*= 8.4 Hz, 1H, H₅), 3.81 (s, 2H), 3.46 (dd, *J*= 6.9, 1.9 Hz, H₁), 2.88 (m, 4H, 2H₃, H₄, H_{6anti}), 1.76 (t, *J*= 8.1 Hz, H_{6syn}); ¹³C NMR (100 MHz, CDCl₃) δ 139.0, 128.5, 128.3, 127.0, 68.8, 59.0, 55.3, 54.6, 48.0, 35.8; HRMS *m/z* found 252.0383, calcd for C₁₂H₁₅NBr (M+H) 252.0383.

***N*-(Benzyloxycarbonyl)-5-*anti*-bromo-6-*anti*-fluoro-2-azabicyclo[2.1.1]hexane (15)**

To a solution of 2-azabicyclo[2.2.0]hex-5-ene **12^{7b}** (1.30 g, 0.006 mol) in MeNO₂ (50 mL) was added NBS (2.15 g, 0.012 mol) at 0 °C followed by Et₃N·3HF (2.92 g, 0.018 mol) dropwise over a period of 10 min.¹² The reaction was brought to room temperature and stirred for 20 h. Then the reaction mixture was diluted with CH₂Cl₂ (125 mL) and washed with saturated aqueous NaHCO₃ solution (50 mL). The organic layer was dried over anhydrous Na₂SO₄, concentrated *in vacuo* and the residue was purified by flash chromatography (1:3 ether/hexanes) to afford 997 mg (53%) of bromofluoride **15** as a colorless oil at *R_f*= 0.49 (1:1 ether/hexanes); ¹H NMR (400 MHz, CDCl₃) δ 7.41-7.29 (m, 5H), 5.18 (d, *J*= 12.3 Hz, 1H), 5.14 (d, *J*= 12.3 Hz, 1H), 4.99 (dd, *J*= 59.1, 7.3 Hz, 1H, H₅), 4.55 (br d, *J*= 7.2 Hz, 1H, H₆), 4.11 (dd, *J*= 7.3, 3.1 Hz, 1H, H₁), 3.61 (ddd, *J*= 9.1, 3.2, 1.2 Hz, 1H, H₃), 3.51 (dt, *J*= 9.1, 1.3 Hz, 1H, H_{3'}), 3.13 (brdd, *J*= 7.3, 3.6 Hz, 1H, H₄); ¹³C NMR (100 MHz, CDCl₃) δ 154.9, 136.0, 128.5, 128.3, 128.0, 99.7 (*J_{C,F}*= 226.8 Hz), 67.4, 64.6, 49.8, 49.1 (*J_{C,F}*= 17.5 Hz), 48.1; ¹⁹F NMR (282 MHz, CDCl₃) δ -204.75 (d, *J*= 58.9 Hz), -205.83 (d, *J*= 58.9 Hz); HRMS *m/z* found 336.0014, 338.0005, calcd for C₁₃H₁₃NO₂FBr⁷⁹ and ⁸¹Na (M + Na) 336.0011, 337.9991.

***N*-Benzyl-5-*anti*-bromo-6-*anti*-fluoro-2-azabicyclo[2.1.1]hexane (11)**

To a solution of fluorobromide **15** (990 mg, 3.2 mmol) in methanol (25 mL) was added Pd(OH)₂ (99 mg). The solution was degassed *in vacuo* for 5 min and stirred at room temperature under a H₂ balloon for 1 h. The reaction mixture was then filtered through Celite, the solvent was removed *in vacuo*, the crude amine was dissolved in CH₃CN (17 mL) and then Et₃N (1.3 g, 4 mmol) followed by BnBr (807 mg, 1.5 mmol) were added dropwise. The solution was stirred at room temperature for 3 days followed by removal of solvent *in vacuo* to give the residue, which was chromatographed to give 494 mg (58%) of bromoamine **11** as a light orange oil at *R_f*= 0.79 (1:5 ether/hexanes); ¹H NMR (400 MHz, CDCl₃) δ 7.40-7.25 (m, 5H), 5.17 (dd, *J*= 60.6, 7.3 Hz, 1H, H₅), 4.39 (dd, *J*= 7.4, 3.2 Hz, 1H, H₆), 3.88 (d, *J*= 13.2, 1H), 3.77 (d, *J*= 13.2, 1H), 3.55 (dd, *J*= 6.8, 1.8 Hz, 1H, H₁), 3.07 (ddt, *J*= 6.8, 4.4 and 1.2 Hz, 1H, H₄), 3.03 (dt, *J*= 9.0 and 1.2 Hz, 1H, H₃), 2.74 (ddd, *J*= 9.0, 4.0, 1.2 Hz, 1H, H_{3'}); ¹³C NMR (100 MHz, CDCl₃) δ 137.9, 128.4 (2C overlap), 127.3, 100.1 (*J_{C,F}*= 222.3 Hz), 68.4 (*J_{C,F}*= 18.7 Hz, C₁), 58.5, 52.9 (*J_{C,F}*= 5.0 Hz), 51.4 (*J_{C,F}*= 17.1 Hz, C₄), 49.4 (*J_{C,F}*= 3.0 Hz); ¹⁹F NMR (282 MHz, CDCl₃) δ -208.68 (d, *J*= 60.6 Hz); HRMS *m/z* 270.0275, calcd for C₁₂H₁₃BrFN (M) 270.0288.

***N*-Benzyl-5-*anti*,6-*anti*-diacetoxo-2-azabicyclo[2.1.1]hexane (16a) and *N*-Benzyl-5-*anti*-acetoxo-6-*anti*-bromo-2-azabicyclo[2.1.1]hexane (17)**

General Method A (DMF)—To a solution of dibromide **9** (200 mg, 0.604 mmol) in DMF (20 mL) under argon there was added cesium acetate (696 mg, 3.63 mmol). After stirring at 60 °C for 5 days, the reaction mixture was allowed to reach room temperature. Brine (10 mL) was added and the solvent was extracted with ether (3 × 20 mL). The combined ether

extracts were washed with water (20 mL) and dried over Na₂SO₄. The dried ether was evaporated and the residue was chromatographed on silica gel (hexanes/ether 2:1) to give 70 mg (40%) of diacetate **16a** as an orange color oil at R_f = 0.27 (1:1 hexanes/ether) as an oil, 78 mg (42%) of bromoacetate **17** as an orange color oil at R_f = 0.53 (1:1 hexanes/ether), and 19 mg (10%) of starting material. For diacetate **16a**, ¹H NMR (400 MHz, CDCl₃) δ 7.43-7.23 (m, 5H, Ph), 4.99 (s, 2H, H₅ and H₆), 3.91 (s, 2H, CH₂Ph), 3.56 (d, J = 6.9 Hz, 1H, H₁), 3.04 (d, J = 6.9 Hz, 1H, H₄), 3.03 (s, 2H, 2H₃), 2.10 (s, 6H, 2COCH₃); ¹³C NMR (100 MHz, CDCl₃) δ 170.8, 138.2, 128.7, 128.4, 127.3, 81.7 (C₅ and C₆), 65.5, 58.6, 52.2, 47.7, 21.0; HRMS m/z 290.1399, calcd for C₁₆H₂₀NO₄ (M+H) 290.1392. For bromoacetate **17**, ¹H NMR (400 MHz, CDCl₃) δ 7.41-7.27 (m, 5H, Ph), 4.91 (d, J = 7.0 Hz, 1H), 4.34 (d, J = 7.1 Hz, 1H), 3.94 (d, J = 13.1 Hz, 1H), 3.86 (d, J = 13.1 Hz, 1H), 3.62 (d, J = 6.7 Hz, 1H, H₁), 3.11 (d, J = 6.7 Hz, 1H, H₄), 3.04 (d, J = 8.8 Hz, 1H, H₃), 2.92 (br, 1H, H_{3'}), 2.13 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 170.9, 137.7, 128.6, 128.5, 127.4, 82.3, 68.2, 58.4, 53.7, 50.3, 50.0, 21.2; HRMS m/z 310.0410, 312.0424, calcd for C₁₄H₁₇NO₂^{79, 81}Br (M+H) 310.0443, 312.0422.

***N*-Benzyl-5-*anti*,6-*anti*-dihydroxy-2-azabicyclo[2.1.1]hexane (16b)**

To a solution of diacetate **16a** (50 mg, 0.173 mmol) in methanol (3 mL) under argon there was added triethylamine (175 mg, 1.728 mmol). The solution was stirred at room temperature overnight and concentrated under reduced pressure. Purification of the obtained residue by flash chromatography (9.5:0.5 CH₂Cl₂/MeOH) afforded 27 mg (76%) of diol **16b** as a light orange oil at R_f = 0.54 (CH₂Cl₂/MeOH 9:1); ¹H NMR (400 MHz, CDCl₃) δ 7.40-7.28 (m, 5H), 4.59 (s, 2H, H₅ and H₆), 3.89 (s, 2H), 3.57 (br, 2H, 2OH), 3.21 (d, J = 7.0 Hz, 1H, H₁), 2.97 (s, 2H, 2H₃), 2.64 (d, J = 6.9 Hz, 1H, H₄); ¹³C NMR (100 MHz, CDCl₃) δ 137.7, 128.8, 128.5 and 127.4, 81.9 (C₅ and C₆), 67.9, 58.9, 52.7, 50.4; HRMS m/z 206.1173, calcd for C₁₂H₁₆NO₂ (M+H) 206.1181.

***N*-Benzyl-5-*anti*,6-*anti*-difluoro-2-azabicyclo[2.1.1]hexane (18) and *N*-Benzyl-3-formylpyrrole (19). (From diol 16b)**

To a solution of diol **16b** (25 mg, 0.122 mmol) in CH₂Cl₂ (0.7 mL) under argon there was added BAST (81 mg, 0.365 mmol) dropwise at -78 °C. The resulting mixture was brought to room temperature and stirred overnight. The solution was diluted with CH₂Cl₂ (1.3 mL) washed with brine (0.5 mL) and water (0.5 mL) and then the CH₂Cl₂ layer was dried over Na₂SO₄. The organic layer was concentrated under reduced pressure and purification of obtained residue by preparative TLC (1:1 hexanes/ether) gave 6 mg (24%) of difluoro compound **18** at R_f = 0.37 (1:1 hexanes/ether) and 9 mg (40%) aldehyde **19** at R_f = 0.13 (1:1 hexanes/ether). For **18**, ¹H NMR (400 MHz, CDCl₃) δ 7.35-7.25 (m, 5H), 5.34 (m, AA'XX' pattern, 2H, H₅ and H₆), 3.82 (s, 2H), 3.45 (dt, J = 7.2, 1.9 Hz, 1H, H₁), 2.99 (m, 1H, H₄), 2.92 (s, 2H, 2H₃); ¹³C NMR (100 MHz, CDCl₃) δ 138.1, 128.4 (2C), 127.3, 100.6 and 98.3 (m, AA'XX' pattern, 2C, C₅ and C₆), 65.5 (t, J = 18.2 Hz, C₁), 58.7, 50.5 (t, J = 7.3 Hz), 49.2 (t, J = 18.1 Hz, C₄); ¹⁹F NMR (282 MHz, CDCl₃) δ -217.3 (m). HRMS m/z 210.1089, calcd for C₁₂H₁₄NF₂ (M+H) 210.1094.

***N*-Benzyl-5-*anti*,6-*anti*-diazido-2-azabicyclo[2.1.1]hexane (20) and *N*-Benzyl-6-*anti*-azido-5-*anti*-bromo-2-azabicyclo[2.1.1]hexane (21). (DMF)**

According to general method A, sodium azide (15 mg, 0.24 mmol) was added to a solution of crystalline dibromide **9** (15 mg, 0.045 mmol) in DMF (2.5 mL) under an air atmosphere. The mixture was allowed to stir at 60 °C for 8 d. Workup and chromatography of the residue using silica gel (5:1 hexane/ether) gave 9.3 mg of a mixture of dibromide **9** (2.6 mg), 2.8 mg (34%) of diazide **20** at R_f = 0.5 (1:1 hexane/ether), and 4.0 mg (49%) of bromoazide **21** at R_f = 0.6. In two trials with non-crystalline dibromide **9** a small amount (<6%) of aldehyde **19**

was observed at $R_f = 0.35$. For diazide **20**, ^1H NMR (CDCl_3 , 400 Hz) δ 7.25 (m, 5H), 4.14 (s, 2H), 3.75 (s, 2H), 3.31 (d, $J = 7.0$ Hz, 1H, H_1), 2.85 (s, 2H, 2H_3), 2.81 (d, $J = 7.0$ Hz, 1H, H_4); ^{13}C NMR (CDCl_3 , 100 Hz) δ 138.4, 128.9, 128.9, 127.8, 68.4, 67.3, 59.0, 53.9, 48.2; HRMS m/z calcd for $\text{C}_{12}\text{H}_{14}\text{N}_7$ ($\text{M}+\text{H}$) 256.1259, found 256.1263. For bromoazide **22**, ^1H NMR (CDCl_3 , 400 Hz) δ = 7.25 (m, 5H), 4.22 (d, $J = 7.0$ Hz, 1H), 4.18 (d, $J = 7.0$ Hz, 1H), 3.77 (two d, $J = 13.2$ Hz, 2H, CH_2Ph), 3.41 (d, $J = 6.6$ Hz, 1H, H_1), 2.93 (m, 2H, H_3+H_4), 2.72 (d, $J = 9.1$ Hz, 1H, H_3); ^{13}C NMR (CDCl_3 , 100 Hz) δ 138.3, 128.9, 128.9, 127.8, 69.8, 68.9, 59.0, 54.8, 50.5 (2C); HRMS m/z 294.0483, calcd for $\text{C}_{12}\text{H}_{14}\text{N}_4\text{Br}$ ($\text{MBr}^{79} + \text{H}$) 294.0481 and 296.0465, calcd for $\text{C}_{12}\text{H}_{14}\text{N}_4\text{Br}$ ($\text{MBr}^{81} + \text{H}$) 296.0461.

***N*-Benzyl-5-*anti*-6-*anti*-di-(phenylthio)-2-azabicyclo[2.1.1]hexane (22) and *N*-Benzyl-5-*anti*-bromo-6-*anti*-(phenylthio)-2-azabicyclo[2.1.1]hexane (23)**

According to general method B, to a solution of dibromide **9** (50 mg, 0.15 mmol) in dry DMSO (1 mL) there was added NaSPh (120 mg, 0.906 mmol) under argon and the reaction mixture was maintained at 60 °C for 5 h. The usual workup and chromatography (prep tlc, 1:2 ether/hexanes) gave di(phenylthio) ether **22** (22 mg, 37%) at $R_f = 0.53$ (1:2 ether/hexanes) and bromo(phenylthio) ether **23** (16 mg, 29%) at $R_f = 0.59$ (1:2 ether/hexanes) as light orange colored oils and the starting dibromide **9** (2 mg, 4%) at $R_f = 0.73$ (1:2 ether/hexanes) as off-white solid. For di(phenylthio) ether **22**, ^1H NMR (400 MHz, CDCl_3) δ 7.44-7.23 (m, 15H), 3.94 (s, 2H, H_5 and H_5'), 3.80 (s, 2H, CH_2Ph), 3.71 (d, $J = 6.6$ Hz, 1H, H_1), 3.16 (d, $J = 6.6$ Hz, 1H, H_4), 3.06 (s, 2H, H_3); ^{13}C NMR (100 MHz, CDCl_3) δ 138.5 (br, 2C), 129.2, 129.0, 128.5, 128.4, 127.2, 126.1, 71.3, 58.9, 56.8, 56.6, 51.6; HRMS m/z 390.1361 calcd for $\text{C}_{24}\text{H}_{24}\text{NS}_2$ ($\text{M}+\text{H}$) 390.1345. For the bromo(phenylthio) ether **23**, ^1H NMR (400 MHz, CDCl_3) δ 7.37-7.18 (m, 10H), 4.27 (d, $J = 7.3$ Hz, 1H, H_6), 3.88 (d, $J = 13.3$ Hz, 1H, CH_2Ph), 3.83 (d, $J = 13.3$ Hz, 1H, CH_2Ph), 3.74 (d, $J = 7.3$ Hz, 1H, H_5), 3.64 (d, $J = 6.5$ Hz, 1H, H_1), 3.13 (d, $J = 6.5$ Hz, 1H, H_4), 2.97 (d, $J = 8.9$ Hz, 1H, H_3), 2.94 (d, $J = 8.9$ Hz, 1H, H_3); ^{13}C NMR (100 MHz, CDCl_3) δ 139.1, 138.0, 129.3, 129.0, 128.5, 128.5, 127.4, 126.2, 71.2, 58.8, 58.3, 55.9, 52.7, 52.0; HRMS m/z 360.0433 calcd for $\text{C}_{18}\text{H}_{19}\text{BrNS}$ ($\text{M}+\text{H}$) 360.0416.

***N*-Benzyl-5-*anti*-acetoxy-2-azabicyclo[2.1.1]hexane (24a). (DMF)**

Following general method A, to a solution of bromide **10** (14 mg, 0.06 mmol) in DMF (8 mL) under argon there was added (72 mg, 0.5 mmol) of AgOAc . The resulting solution was heated for 12 h at 70 °C. Workup and chromatography gave 7 mg (54 %) of acetate **24a** at $R_f = 0.28$ (1:1 hexane/ethyl acetate); ^1H NMR (300 MHz, CDCl_3) δ 7.24 (m, 5H), 4.73 (d, $J = 7.5$ Hz, H_5), 3.82 (d, $J = 13.1$ Hz, 1H, CH_2), 3.74 (d, $J = 13.1$ Hz, 1H, CH_2), 3.39 (dd, $J = 6.6, 1.5$ Hz, H_1), 2.88 (d, $J = 8.7$ Hz, H_3), 2.74 (m, 2H, H_4 and H_3), 2.42 (d, $J = 7.8$ Hz, $\text{H}_{6\text{anti}}$), 2.03 (s, 3H), 1.73 (dd, $J = 7.8, 7.5$ Hz, $\text{H}_{6\text{syn}}$); ^{13}C NMR (100 MHz, CDCl_3) δ 171.1, 130.0, 128.8, 128.4, 127.2, 81.4, 65.5, 58.5, 54.0, 44.4, 32.3, 21.0; HRMS m/z found 232.1315, calcd for $\text{C}_{14}\text{H}_{18}\text{NO}_2$ ($\text{M}+\text{H}$) 232.1315.

***N*-Benzyl-5-*anti*-hydroxy-2-azabicyclo[2.1.1]hexane (24b)**

To a solution of acetate **24a** (3 mg, 0.002 mmol) in methanol (3 mL) was added K_2CO_3 (138 mg, 0.01 mmol) and the solution was stirred at RT for 1 h. After 1 h the base was filtered and the solvent was removed *in vacuo* to give 2.1 mg (84 %) of the alcohol **24b** at $R_f = 0.20$ (1:2 hexane/ethyl acetate); ^1H NMR (300 MHz, CDCl_3) δ 7.36 (m, 5H), 4.18 (brd, $J = 7.2$ Hz, H_5), 3.78 (d, $J = 12.9$ Hz, 1H, CH_2), 3.69 (d, $J = 12.9$ Hz, 1H, CH_2), 3.19 (d, $J = 6.8, 1.8$ Hz, H_1), 2.96 (d, $J = 8.8$ Hz, H_3), 2.64 (brd, $J = 8.1$ Hz, $\text{H}_{6\text{anti}}$), 2.54 (dd, $J = 6.8, 3.0$ Hz, 1H, H_4), 2.48 (d, $J = 8.8$ Hz, H_3), 1.74 (dd, $J = 8.1, 7.2$ Hz, $\text{H}_{6\text{syn}}$); ^{13}C NMR (100 MHz, CDCl_3) δ 128.7, 128.3, 126.9, 80.6, 67.3, 59.1, 55.0, 46.1, 32.3; HRMS m/z 190.1212, calcd for $\text{C}_{12}\text{H}_{15}\text{NO}$ ($\text{M}+\text{H}$) 190.1227.

***N*-(*tert*-Butoxycarbonyl)-5-*anti*-hydroxy-2-azabicyclo[2.1.1]hexane (25)**

To a solution of alcohol **24b** (25 mg, 0.13 mmol) in MeOH (8 mL) there was added Pd(OH)₂ (5 mg) and (BOC)₂O (54 mg, 0.25 mmol). The solution was stirred under 1 atmosphere of hydrogen for 7 h at RT. Afterward, the solution was diluted with 10 mL of MeOH and filtered through Celite. Evaporation of the solvent followed by column chromatography gave 24 mg (92%) of the pure alcohol **25** at R_f = 0.31 (2:1 hexane/ether); ¹H NMR (300 MHz, CDCl₃) δ 4.17 (m, 2H, H₁ and H₅), 3.32 (s, 2H, 2H₃), 2.93 (dm, J = 7.5 Hz, 1H, H₄), 2.70 (m, 1H, H_{6anti}), 1.81 (br, OH), 1.61 (t, J = 7.5 Hz, 1H, H_{6syn}), 1.45 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 155.7, 81.4, 79.5, 63.4, 48.3, 44.1, 36.9, 28.5; HRMS m/z found 222.1104, calcd for C₁₀H₁₇NO₃Na (M + Na) 222.1104.

***N*-Benzyl-5-*anti*-fluoro-2-azabicyclo[2.1.1]hexane (26). (From bromide 10 using AgF)**

To a solution of bromide **10** (33 mg, 0.13 mmol) in CH₃NO₂ (8 mL) at RT under argon there was added AgF (83 mg, 0.65 mmol) and the reaction mixture was heated at 50 °C for 12 h. The AgF was filtered via Celite and the solvent was removed *in vacuo* to give 20 mg (80%) of pure fluoride **26** at R_f = 0.20 (1:2 hexane/ethyl acetate); ¹H NMR (300 MHz, CDCl₃) δ 7.36 (m, 5H), 4.90 (dd, J = 64, 7.2 Hz, H₅), 3.74 (d, J = 13.8 Hz, 1H, CH₂), 3.65 (d, J = 13.8 Hz, 1H, CH₂), 3.35 (brd, J = 6.4 Hz, H₃), 2.88 (b, J = 8.8 Hz, H₃), 2.72 (br, H₄), 2.51 (m, 2H, H₃ and H_{6anti}), 1.90 (ddd, J = 8.0, 7.2, 2.4 Hz, H_{6syn}); ¹³C NMR (75 MHz, CDCl₃) δ 138.6, 128.7, 128.4, 127.2, 98.8 (d, J = 208 Hz), 65.8 and 65.6, 58.9, 53.5, 45.3, 32.1; ¹⁹F NMR (282 MHz, CDCl₃) δ -220.1 (d, J = 64.7 Hz); HRMS m/z found 192.1191, calcd for C₁₂H₁₄NF (M + H) 192.1188.

***N*-Benzyl-5-*anti*-azido-2-azabicyclo[2.1.1]hexane (27)**

Method A. DMF—To a solution of bromide **10** (65 mg, 0.24 mmol) in DMF (10 mL) under argon there was added sodium azide (84 mg, 1.3 mmol). The resulting solution was heated for 12 h at 70 °C. The usual workup and flash chromatography gave 28 mg (51%) of the azide **27** at R_f = 0.39 (1:1 hexane/ether); ¹H NMR (300 MHz, CDCl₃) δ 7.38 (m, 5H), 3.86 (br, J = 7.5 Hz, H₅), 3.72 (d, J = 13.2 Hz, 1H), 3.65 (d, J = 13.2 Hz, 1H), 3.32 (dd, J = 6.3, 2.0 Hz, H₁), 2.86 (brd, J = 9.3 Hz, H₃), 2.67 (m, H₄), 2.61 (d, J = 9.3 Hz, H₃), 2.38 (brd, J = 7.8 Hz, H_{6anti}), 1.69 (dd, J = 7.8, 7.5 Hz, H_{6syn}); ¹³C NMR (100 MHz, CDCl₃) δ 129.0, 128.8, 127.5, 69.5, 67.0, 59.2, 54.9, 45.2 and 33.8; HRMS m/z found 215.1291, calcd for C₁₂H₁₅N₄ (M + H) 215.1282; m/z found 256.1551, calcd for C₁₄H₁₈N₅ (M + CH₃CN + H) 256.1556.

***N*-Benzyl-5-*anti*-(*tert*-butoxycarbonylamino)-2-azabicyclo[2.1.1]hexane (28)**

To a solution of azide **27** (29 mg, 0.13 mmol) in toluene (8 mL) there was added PPh₃ (71 mg, 0.27 mmol) and water (1 mL) and the resultant solution was heated at 60 °C for 4 h. After allowing cooling, the two layers were separated and the water layer was extracted with CH₂Cl₂ (3 × 5 mL). All the organic layers were combined and dried over Na₂SO₄. Solvent was removed *in vacuo* and the amine was dissolved in MeOH to which there was added Et₃N (18 μL, 0.26 mmol) and (BOC)₂O (28 mg, 0.13 mmol). Removal of the solvent followed by flash chromatography gave 34 mg (87%) of the BOC protected amine **28** at R_f = 0.37 (1:3 hexane/ethyl acetate); ¹H NMR (300 MHz, CDCl₃) δ 7.44 (m, 5H), 4.92 (br, 1H, NH), 3.82 (s, 2H), 3.76 (br, H₅), 3.40 (br, H₁), 2.86 (d, J = 8.1 Hz, H₃), 2.72 (br, 2H, H₃ and H₄), 2.32 (brd, J = 7.8 Hz, H_{6anti}), 1.74 (dd, J = 7.8, 8.1 Hz, H_{6syn}), 1.35 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 156.4, 139.3, 128.9 and 128.8, 127.5, 119.5, 79.9, 66.5, 59.0, 55.2, 44.7, 34.3, 34.2, 28.8; HRMS m/z found 289.1917, calcd for C₁₇H₂₅N₂O₂ (M + H) 289.1911; m/z found 311.1749, calcd for C₁₇H₂₄N₂O₂Na (M + Na) 311.1730.

N-Benzyl-5-*anti*-imidazol-1-yl-2-azabicyclo[2.1.1]hexane (29)

Butyllithium (90 μ L, 2.5 M solution in hexanes, 0.226 mmol) was added dropwise to imidazole (15 mg, 0.226 mmol) in anhydrous DMF (0.5 mL) under argon, and the mixture was stirred at 20 °C for 0.25 h. A solution of bromide **10** (19 mg, 0.075 mmol) in anhydrous DMF (0.5 mL) was added, and after stirring at 70 °C for 8 days workup and chromatography ($\text{CH}_2\text{Cl}_2/\text{MeOH}/\text{NH}_4\text{OH}$ 90: 10: 1) the imidazolyl compound **29** was isolated as a light orange colored oil (10 mg, 55%) at R_f = 0.60 ($\text{CH}_2\text{Cl}_2/\text{MeOH}/\text{NH}_4\text{OH}$, 90:10:1); ^1H NMR (400 MHz, CDCl_3) δ 7.54 (s, 1H), 7.43-7.25 (m, 5H), 7.09 (s, 1H), 6.94 (s, 1H), 4.30 (d, J = 7.3 Hz, 1H, H_5), 3.91 (d, J = 13.2 Hz, 1H, Bn), 3.83 (d, J = 13.2 Hz, 1H, Bn), 3.70 (dbr, J = 6.8 Hz, 1H, H_1), 3.14-3.07 (m, 2H, H_3), 2.79 (d, J = 8.7 Hz, 1H, $\text{H}_{6\text{anti}}$), 2.13 (m, 1H, H_4), 1.88 (two d, J = 8.5, 8.5 Hz, 1H, $\text{H}_{6\text{syn}}$); ^{13}C NMR (100 MHz, CDCl_3) δ 138.7, 136.8, 129.4, 128.6, 128.5, 127.3, 119.0, 66.1, 64.4, 58.9, 54.6, 44.1, 33.4; HRMS m/z 240.1495, calcd for $\text{C}_{15}\text{H}_{18}\text{N}_3$ ($\text{M} + \text{H}$) 240.1495.

N-Benzyl-5-*anti*-phenylthio-2-azabicyclo[2.1.1]hexane (30)

Following method B, to a solution of monobromide **10** (22 mg, 0.087 mmol) in dry DMSO (0.6 mL) there was added NaSPh (35 mg, 0.262 mmol) and the reaction mixture was maintained at 60 °C for 5 h under argon. Workup and chromatography (prep tlc, 1:1 ether/hexanes) afforded phenylthio ether **30** (19 mg, 77%) at R_f = 0.42 (1:1 ether/hexanes) as a light orange colored oil; ^1H NMR (400 MHz, CDCl_3) δ 7.50-7.23 (m, 10H), 3.96 (d, J = 13.3 Hz, 1H, CH_2Ph), 3.91 (d, J = 13.3 Hz, 1H, CH_2Ph), 3.72 (d, J = 8.0 Hz, 1H, H_5), 3.54 (dbr, J = 6.6, 1.8 Hz, 1H, H_1), 2.99 (dd, J = 8.7, 1.0 Hz, 1H, H_3), 2.93 (dd, J = 8.7, 1.0 Hz, 1H, H_3), 2.88 (m, 1H, $\text{H}_{6\text{syn}}$), 2.84 (m, 1H, H_4), 1.81 (t, J = 8.0 Hz, 1H, $\text{H}_{6\text{syn}}$); ^{13}C NMR (100 MHz, CDCl_3) δ 138.9, 136.9, 128.9, 128.7, 128.6, 128.4, 127.1, 125.8, 67.3, 58.8, 55.8, 54.4, 45.0, 35.7; HRMS m/z 282.1321 calcd for $\text{C}_{18}\text{H}_{20}\text{NS}$ ($\text{M} + \text{H}$) 282.1311.

N-Benzyl-5-*anti*-iodo-2-azabicyclo[2.1.1]hexane (31)

A solution of NaI (190 mg, 1.269 mmol) in acetone (750 μ L) was added to bromide **10** (16 mg, 0.063 mmol) under argon. The reaction mixture was maintained at reflux for 4 days. The solvent was removed *in vacuo* and the crude was dissolved in CH_2Cl_2 (4 mL) and washed with water (2 mL). The organic layer was separated and the aqueous layer was washed with CH_2Cl_2 (2 $\times$ 2 mL). The organic extracts were combined and dried over Na_2SO_4 . The solvent was removed *in vacuo* and the crude was chromatographed (prep tlc, 1:1 ether/hexanes) to give iodide **31** (14 mg, 74%) at R_f = 0.74 (1:1 ether/hexanes) as a light orange colored oil; ^1H NMR (400 MHz, CDCl_3) δ 7.38-7.24 (m, 5H), 3.95 (d, J = 9.0 Hz, 1H, H_5), 3.80 (two d, J = 13.3, 13.3 Hz, 2H, Bn), 3.46 (dd, J = 6.5, 1.8 Hz, 1H, H_1), 2.86-2.77 (m, 4H, 2 H_3 , H_4 and $\text{H}_{6\text{anti}}$), 1.75 (dd, J = 9.0, 8.0 Hz, 1H, $\text{H}_{6\text{syn}}$); ^{13}C NMR (100 MHz, CDCl_3) δ 139.0, 128.5, 128.4, 127.1, 69.5, 59.1, 54.1, 48.5, 37.9, 30.1; HRMS m/z 300.0243, calcd for $\text{C}_{12}\text{H}_{15}\text{IN}$ ($\text{M} + \text{H}$) 300.0244.

N-Benzyl-6-*anti*-acetoxy-5-*anti*-fluoro-2-azabicyclo[2.1.1]hexane (32a)

Method A (DMF)—To a solution of bromofluoride **11** (900 mg, 3.33 mmol) in DMF (55 mL) under argon there was added cesium acetate (1279 mg, 6.66 mmol). The solution was maintained at 70 °C for 5 days. The usual workup and flash chromatography (1:3 ether/hexanes) afforded 578 mg (64%) of unreacted fluorobromide **11** at R_f = 0.61 (1:1 ether/hexane) and 249 mg (30%) (84% BORSM) of fluoroacetate **32a** at R_f = 0.44 (1:1 ether/hexanes); ^1H NMR (400 MHz, CDCl_3) δ 7.38-7.22 (m, 5H), 5.29-5.08 (m, ABX pattern, 2H, H_5 and H_6) (See supplemental), 3.88 (d, J = 13.2, Hz, 1H), 3.82 (d, J = 13.2, Hz, 1H), 3.48 (dd, J = 7.1, 2.2 Hz, 1H, H_1), 3.05-2.95 (m, 2H, $\text{H}_3 + \text{H}_4$), 2.88 (ddd, J = 9.0, 3.7, 1.2 Hz, 1H, H_3), 2.12 (s, 3H); ^1H NMR (400 MHz, $\text{CDCl}_3 + \text{C}_6\text{D}_6$ 1:1 mixture) δ 7.41-7.22 (m, 5H), 5.26-4.99 (m, ABX pattern, 2H, H_5 and H_6), 3.73 (d, J = 13.2, Hz, 1H), 3.66 (d, J =

13.2, Hz, 1H), 3.48 (dd, $J = 7.1, 2.2$ Hz, 1H, H₁), 2.86 (t, $J = 6.0$ Hz, 1H, H₄), 2.79-2.62 (m, 2H, 2H₃), 2.01 (s, 3H); ¹H NMR (400 MHz, C₆D₆) δ 7.44-7.22 (m, 5H), 5.21-4.96 (m, ABX pattern, 2H, H₅ and H₆), 3.61 (d, $J = 13.2$, Hz, 1H), 3.55 (d, $J = 13.2$, Hz, 1H), 3.51 (dd, $J = 7.1, 2.1$ Hz, 1H, H₁), 2.78 (m, 1H, H₄), 2.57 (br d, $J = 9.0$ Hz, 1H, H₃), 2.50 (ddd, $J = 9.0, 3.6, 1.2$ Hz, 1H, H₃), 1.92 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 171.2, 138.2, 128.5, 128.4 and 127.2, 99.5 ($J_{C,F} = 219.0$ Hz, C₅), 81.3 ($J_{C,F} = 3.6$ Hz), 65.5 ($J_{C,F} = 18.4$ Hz, C₁), 58.7, 51.4 ($J_{C,F} = 6.7$ Hz), 48.4 ($J_{C,F} = 17.7$ Hz, C₄), 21.0; ¹⁹F NMR (282 MHz, CDCl₃) δ -214.63 (d, $J = 60.9$ Hz); HRMS m/z 250.1224, calcd for C₁₄H₁₇FNO₂ (M + H) 250.1238.

***N*-Benzyl-5-*anti*-fluoro-6-*anti*-hydroxy-2-azabicyclo[2.1.1]hexane (32b)**

To a solution of fluoroacetate **32a** (575 mg, 2.306 mmol) in methanol (35 mL) under argon there was added Et₃N (3212 μ L, 23.066 mmol). The solution was stirred at room temperature for 20 h and concentrated under reduced pressure. Purification of the obtained residue by flash chromatography (0.5:9.5 MeOH/CH₂Cl₂) afforded 459 mg (96%) of fluoroalcohol **32b** at $R_f = 0.62$ (1:9 MeOH/CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.40-7.19 (m, 5H), 5.41 (dd, $J = 61.8, 8.0$ Hz, 1H, H₅), 4.56 (d, $J = 8.0$ Hz, 1H, H₆), 3.83 (s, 2H), 3.33 (dd, $J = 7.2, 2.1$ Hz, 1H, H₁ and br, 1H, OH), 2.93 (s, 2H, 2H₃), 2.82 (brdd, $J = 7.2, 5.2$, Hz, 1H, H₄); ¹³C NMR (100 MHz, CDCl₃) δ 137.8, 128.6, 128.5 and 127.4, 102.2 ($J_{C,F} = 208.7$ Hz, C₅), 82.4, 66.9 ($J_{C,F} = 16.3$ Hz, C₁), 58.8, 51.6 ($J_{C,F} = 7.8$ Hz), 50.2 ($J_{C,F} = 16.3$ Hz, C₄); ¹⁹F NMR (282 MHz, CDCl₃) δ -213.63 (dd, $J = 62.4, 3.9$ Hz); the extra 3.9 Hz may be due to H-bonding. Calculated couplings for the related *N*-methyl fluoroalcohol are 62.53 and 11.8 Hz; HRMS m/z 208.1109, calcd for C₁₂H₁₅FNO (M + H) 208.1132.

***N*-(*t*-Butoxycarbonyl)-5-*anti*-fluoro-6-*anti*-hydroxy-2-azabicyclo[2.1.1]hexane (33)**

To a solution of fluoroalcohol **32b** (250 mg, 1.206 mmol) in MeOH (10 mL) there was added palladium hydroxide (20 wt % Pd on carbon) (38 mg) and (Boc)₂O (316 mg, 1.447 mmol). The resulting solution was stirred at RT under hydrogen for 6 h. Then the solution was filtered through Celite and washed with MeOH (10 mL). The filtrate was evaporated to give an oily solid, n-heptane (20 mL) was added to the residue, and solvent was again evaporated. Then n-heptane (30 mL) was added to the residue, and after stirring at room temperature for 2 h, the separated solid was filtered and dried under reduced pressure to afford 237 mg (91%) of fluoroalcohol **33** as an off-white solid at $R_f = 0.71$ (1:9 MeOH/CH₂Cl₂); mp 95–97 °C; ¹H NMR (400 MHz, CDCl₃) δ 5.10 (dd, $J = 60.8, 7.8$ Hz, 1H, H₅), 4.28 (d, $J = 7.7$ Hz, 1H, H₆), 4.22 (br s, 1H, H₁), 3.47 (d, $J = 9.1$ Hz, 1H, H₃), 3.40 (d, $J = 9.0$ Hz, 1H, H_{3'}), 3.08 (br s, 1H, OH), 2.83 (br t, $J = 6.1$ Hz, 1H, H₄), 1.43 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 154.9, 101.9 ($J_{C,F} = 214.2$ Hz, C₅), 84.1, 80.4, 63.8 (br), 48.1 ($J_{C,F} = 16.3$ Hz), 46.0 (br), 28.3; ¹⁹F NMR (282 MHz, CDCl₃) δ -209.3 (d, $J = 57.6$ Hz), -210.3 (d, $J = 57.6$ Hz) (No F-HO splitting was observed.); HRMS m/z 240.1018, calcd for C₁₀H₁₆FNO₃Na(M + Na) 240.1012.

***N*-Benzyl-6-*anti*-azido-5-*anti*-fluoro-2-azabicyclo[2.1.1]hexane (34)**

Method A (DMF)—Sodium azide (144 mg, 2.22 mmol) and tetrabutylammonium chloride (30 mg) were added to a solution of fluorobromide **11** (200 mg, 0.740 mmol) in dry DMF (15 mL) under argon. The reaction mixture was maintained at 70 °C for 5 days. Workup and flash chromatography (1:4 ether/hexanes) afforded 74 mg (43%) (62% BORSM) of fluoroazide **34** as an oil at $R_f = 0.59$ (1:1 ether/hexanes) and 62 mg (31%) of starting material **11** at $R_f = 0.69$; after two column separations, for **34**; ¹H NMR (400 MHz, CDCl₃) δ 7.35-7.27 (m, 5H), 5.21 (dd, $J = 60.9, 7.1$ Hz, 1H, H₅), 4.31 (dd, $J = 7.1, 2.9$ Hz, 1H, H₆), 3.85 (d, $J = 13.1$, 1H), 3.79 (d, $J = 13.2$, 1H), 3.43 (dd, $J = 7.1, 2.0$ Hz, 1H, H₁), 3.00 (dt, $J =$

9.0, 1.3 Hz, 1H, H₃), 2.96 (ddt, $J = 7.1, 4.7, 1.2$ Hz, 1H, H₄), 2.85 (ddd, $J = 9.1, 3.7, 1.2$ Hz, 1H, H_{3'}); ¹³C NMR (100 MHz, CDCl₃) δ 138.0, 128.5, 128.4 and 127.4, 99.6 ($J_{C,F} = 220.2$ Hz, C₅), 67.7 ($J_{C,F} = 4.2$ Hz), 66.3 ($J_{C,F} = 18.1$ Hz), 58.7, 52.1 ($J_{C,F} = 7.1$ Hz), 48.4 ($J_{C,F} = 17.3$ Hz); ¹⁹F NMR (282 MHz, CDCl₃) δ -216.11 (d, $J = 60.4$ Hz); HRMS m/z 233.1202, calcd for C₁₂H₁₄FN₄ (M + H) 233.1202.

***N*-Benzyl-6-*anti*-amino-5-*anti*-fluoro-2-azabicyclo[2.1.1]hexane (35)**

To a solution of fluoroazide **34** (70 mg, 0.301 mmol) in toluene (20 mL) and water (2.5 mL) there was added triphenylphosphine (166 mg, 0.633 mmol). The reaction mixture was heated to 60 °C for 5 h. After cooling to room temperature the organic layer was separated and the aqueous layer was extracted with methylene chloride (2 × 5 mL). The combined organic layers were dried over Na₂SO₄. Filtration, removal of solvent, and purification by flash chromatography (1–10 % methanol in methylene chloride) afforded 53 mg (85%) of fluoroamine **35** at $R_f = 0.40$ (1:9 MeOH/CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.40–7.23 (m, 5H), 5.27 (dd, $J = 62.3, 7.4$ Hz, 1H, H₅), 3.83 (d, $J = 13.3$, 1H), 3.78 (d, $J = 13.3$, 1H), 3.73 (dd, $J = 7.5, 1.3$ Hz, 1H, H₆), 3.20 (dd, $J = 7.0, 2.1$ Hz, 1H, H₁), 2.89–2.83 (m, 2H, H₃), 2.68 (ddt, $J = 7.1, 5.2, 1.2$ Hz, 1H, H₄), 2.20 (br s, 2H, NH₂); ¹³C NMR (100 MHz, CDCl₃) δ 138.6, 128.4, 128.2 and 127.0, 101.9 ($J_{C,F} = 212.1$ Hz, C₅), 67.7 ($J_{C,F} = 16.2$ Hz), 63.8 ($J_{C,F} = 2.1$ Hz), 58.8, 52.9 ($J_{C,F} = 8.2$ Hz), 50.3 ($J_{C,F} = 16.3$ Hz); ¹⁹F NMR (282 MHz, CDCl₃) δ -213.55 (brd, $J = 63.1$ Hz); HRMS m/z 207.1301, calcd for C₁₂H₁₆FN₂ (M + H) 207.1298.

***N*-Benzyl-6-*anti*-acetamido-5-*anti*-fluoro-2-azabicyclo[2.1.1]hexane (36)**

DMAP (44 mg, 0.3636 mmol) was added to the solution of fluoroamine **35** (25 mg, 0.1212 mmol) in dry methylene chloride (3 mL) under argon. The resulting solution was cooled to 0 °C and acetyl chloride (26 μ L, 0.3636) was added dropwise. The reaction mixture was allowed to room temperature and stirred for 3 h. The reaction mixture was then diluted with CH₂Cl₂ (7 mL), washed with water (3 × 5 mL) and dried over Na₂SO₄. Filtration, removal of solvent and purification by preparative thin layer chromatography (1:9 MeOH/CH₂Cl₂) afforded 19 mg (63%) of fluoroacetamide **36** at $R_f = 0.54$ (1:9 MeOH/CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.41–7.22 (m, 5H), 6.54 (br s, 1H, NH), 5.34 (dd, $J = 62.5, 7.4$ Hz, 1H, H₅), 4.79 (ddd, $J = 9.3, 7.4, 1.8$ Hz, 1H, H₆), 3.91 (d, $J = 13.2$, 1H), 3.84 (d, $J = 13.2$, 1H), 3.33 (dd, $J = 7.1, 2.5$ Hz, 1H, H₁), 3.07 (br d, $J = 9.1$, Hz, 1H, H₃), 2.85 (br dd, $J = 9.1, 4.1$ Hz, 1H, H_{3'}), 2.78 (ddt, $J = 7.1, 5.7, 1.2$ Hz, 1H, H₄), 2.02 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 170.2, 138.1, 128.6, 128.4 and 127.3, 101.8 ($J_{C,F} = 209.0$ Hz, C₅), 67.0 ($J_{C,F} = 18.6$ Hz), 58.8, 58.6 ($J_{C,F} = 3.2$ Hz), 52.5 ($J_{C,F} = 7.1$ Hz), 49.2 ($J_{C,F} = 16.4$ Hz), 23.7; ¹⁹F NMR (282 MHz, CDCl₃) δ -211.80 (brd, $J = 63.0$ Hz); HRMS m/z 249.1414, calcd for C₁₄H₁₈FN₂O (M + H) 249.1403.

***N*-Benzyl-5-*anti*-fluoro-6-*anti*-phenylthio-2-azabicyclo[2.1.1]hexane (37)**

According to method B, to a solution of bromofluoride **11** (26 mg, 0.096 mmol) in dry DMSO (0.6 mL) there was added NaSPh (38 mg, 0.289 mmol) and the reaction mixture was maintained at 60 °C for 9 days under argon. The usual workup and chromatography (prep tlc, 1:3 ether/hexanes) afforded fluoro(phenylthio) ether **37** (20 mg, 69%) at $R_f = 0.26$ (1:3 ether/hexanes) as a light orange colored oil; ¹H NMR (400 MHz, CDCl₃) δ 7.36–7.18 (br, 10H), 5.13 (dd, $J = 61.8, 6.7$ Hz, 1H, H₅), 3.88 (d, $J = 13.2$ Hz, 1H), 3.88–3.84 (m, 1H, H₆), 3.81 (d, $J = 13.2$ Hz, 1H), 3.54 (dd, $J = 6.8, 2.1$ Hz, 1H, H₁), 3.11 (dt, $J = 9.0, 1.2$ Hz, 1H, H₃), 3.01 (m, 1H, H₄), 2.78 (ddd, $J = 9.0, 3.9, 1.2$ Hz, 1H, H_{3'}); ¹³C NMR (100 MHz, CDCl₃) δ 138.2, 129.1, 129.0, 128.5, 128.4, 127.3, 126.1, 99.9 (d, $J = 216.4$ Hz), 68.5 (d, $J = 18.7$ Hz), 59.9, 54.6 (d, $J = 4.6$ Hz), 53.6 (d, $J = 6.4$ Hz), 50.3 (d, $J = 17.0$ Hz); ¹⁹F NMR

(282 Hz, CDCl₃) δ -210.2 (d, J = 62.4 Hz); HRMS m/z 300.1226 calcd for C₁₈H₁₉FNS (M + H) 300.1217.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Acknowledgment is made to the National Science Foundation (CHE 0515635) and the National Institutes of Health (R01 AR044276). We thank Alex Shaffer for assistance and Hans Reich and David Dalton for helpful discussions.

References

1. For a review of nonproteinogenic amino acids from 4-hydroxyproline, see: Remuzon P. *Tetrahedron*. 1996; 52:13803. For examples of the utility of 4-hydroxyprolines, see also: Krow GR, Lin G, Yu F. *J Org Chem*. 2005; 70:590. [PubMed: 15651806] references 2–12 and Trabocchi A, Rolla M, Menchi G, Guarno A. *Tetrahedron Lett*. 2005; 46:7813.
2. For a recent example, see: Deppermann N, Prenzel AHGP, Beitat A, Maison W. *J Org Chem*. 2009; 74:4267. [PubMed: 19391606] Zanardi F, Burreddu P, Rassu G, Auzzas L, Battistini L, Curti C, Sartori A, Nicastro G, Menchi G, Cini N, Bottonocetti A, Raspanti S, Casiraghi G. *J Med Chem*. 2008; 51:1771. [PubMed: 18303826] For further references, see: Krow GR, Huang Q, Lin G, Centafont RA, Thomas AM, Gandla D, DeBrosse C, Carroll PJ. *J Org Chem*. 2006; 71:2090. especially references 1–6. [PubMed: 16496997]
3. For fluoropyrrolidines, see: Giardina G, Dondio G, Grugni M. *Synlett*. 1995; 43:55. For leading references to 4-fluoroproline and 5-fluoromethanoproline, see: Jenkins CL, Lin G, Duo J, Rapolu D, Guzei IA, Raines RT, Krow GR. *J Org Chem*. 2004; 69:8565. [PubMed: 15575731]
4. For 4-thioproline, see: Williams JM, Brands KMJ, Skerlj RT, Jobson RB, Marchesini G, Conrad KM, Pipik B, Savary KA, Tsay FR, Houghton PG, Sidler DR, Dolling UH, DiMichele LM, Novak TJ. *J Org Chem*. 2005; 70:7479. [PubMed: 16149774] Azami H, Barrett D, Tanaka A, Sasaki H, Matsuda K, Chiba T, Matsumoto Y, Matsumoto S, Morinaga C, Ishiguro K, Tawara S, Sakane K, Takasugi H. *Bioorg Med Chem Lett*. 1995; 5:2199. Kemp DS, Curran TP, Davis WM, Boyd JG, Muendel C. *J Org Chem*. 1991; 56:6672. For a 4-thiopyrrolidine, see: Shibata T, Iono K, Sugimura Y. *Heterocycles*. 1986; 24:1331.
5. For leading references with bridged pyrrolidines, see: Bunch L, Liljefors T, Greenwood JR, Frydenvang K, Brauner-Osborne H, Krogsgaard-Larsen P, Madsen U. *J Org Chem*. 2003; 68:1489. [PubMed: 12585893] Hart BP, Rapoport H. *J Org Chem*. 1999; 64:2050. [PubMed: 11674299] Han W, Pelletier JC, Mersinger L, Ketner CA, Hodge CN. *Org Lett*. 1999; 1:1875. [PubMed: 10836047]
6. For biologically interesting 2-azabicyclo[2.1.1]hexanes, see: Lescop C, Mevellec L, Huet F. *J Org Chem*. 2001; 66:4187. [PubMed: 11397152] Piotroski DW. *Synlett*. 1999:1091. Esslinger CS, Koch HP, Kavanaugh MP, Philips DP, Chamberlin AR, Thompson CM, Bridges RJ. *Bioorg Med Chem Lett*. 1998; 8:3101. [PubMed: 9873684] Koch HP, Kavanaugh MP, Esslinger CS, Zerangue N, Humphrey JM, Amara SG, Chamberlain AR, Bridges RJ. *Mol Pharmacol*. 1999; 56:1095. [PubMed: 10570036] Mapelli C, van Halbeek H, Stammer CH. *Biopolymers*. 1990; 29:407. [PubMed: 2158826] Bell EA, Qureshi MY, Pryce RJ, Janzen DH, Lemke P, Clardy J. *J Am Chem Soc*. 1980; 102:1409. Park TH, Ha YH, Jeong DY. Patent Application WO. 98-KR246 19989898. *Chem Abstr*. 1999; 130:182388. Pirrung MC. *Tetrahedron Lett*. 1980; 21:4577. Hughes P, Martin M, Clardy J. *Tetrahedron Lett*. 1980; 21:4579. Kite GC, Ireland H. *Phytochemistry*. 2002; 59:163. [PubMed: 11809451] Juvvadi P, Dooley DJ, Humblet CC, Lu GH, Lunney EA, Panek RL, Skeeane R, Marshall GR. *Int J Peptide Protein Res*. 1992; 40:163. [PubMed: 1335995] Piela L, Nemethy G, Scheraga HA. *J Am Chem Soc*. 1987; 109:4477. Montelione GT, Hughes P, Clardy J, Scheraga HA. *J Am Chem Soc*. 1986; 108:6765. Talluri S, Montelione BT, van Duyne G, Piola L, Clardy J, Scheraga HA. *J Am Chem Soc*. 1987; 109:4473. Gaoni Y. *Org Prep Proced Int*. 1995; 27:185. Gaoni Y, Chapman AG, Parvez N, Pook PCK, Jane DE. *J Med Chem*. 1994; 37:4288. [PubMed: 7996540] Rammeloo T, Stevens CV, De Kimpe N. *J Org Chem*. 2002; 67:6509. [PubMed: 12201774] Rammeloo T, Stevens CV, De Kimpe N. *J Chem Soc, Chem Commun*. 2002:250. Malpass JR, Patal

- AB, Davies JW, Fulford SY. *J Org Chem*. 2003; 68:9348. [PubMed: 14629156] Stevens CV, Smaghe G, Rammeloo T, De Kimpe N. *J Agric Food Chem*. 2005; 53:1945. [PubMed: 15769118] Patel AB, Malpass JR. *J Med Chem*. 2008; 51:7005. [PubMed: 18841955]
7. For 5(6)-substituted methanoproline, see ref. 3b and: Krow GR, Lin G, Fang Y. *J Org Chem*. 2005; 70:590. [PubMed: 15651806] Krow GR, Lin G, Rapolu D, Fang Y, Lester WS, Herzon SB, Sonnet PE. *J Org Chem*. 2003; 68:5292. [PubMed: 12816491]
8. Kim W, George A, Evans M, Conticello VP. *ChemBioChem*. 2004; 5:928. [PubMed: 15239049]
9. For a review of synthetic approaches to 2-azabicyclo[2.1.1]hexanes, see: Krow GR, Cannon KC. *Heterocycles*. 2004; 62:877.
10. For 3-alkyl(aryl),5(6)-heteroatom-substituted methanopyrrolidines, see: Krow GR, Lin G, Yu F. *J Org Chem*. 2005; 70:590. [PubMed: 15651806] Krow GR, Yuan J, Lin G, Sonnet PE. *Org Lett*. 2002; 4:1259. [PubMed: 11950337] Krow GR, Lee YB, Lester WS, Liu N, Yuan J, Duo J, Herzon SB, Nguyen Y, Zacharias D. *J Org Chem*. 2001; 66:1805. [PubMed: 11262131] Krow GR, Lester WS, Liu N, Yuan J, Hiller A, Duo J, Herzon SB, Nguyen Y, Cannon K. *J Org Chem*. 2001; 66:1811. [PubMed: 11262132] For other 5(6)-heteroatom substituted methanopyrrolidines, see: Krow GR, Lee YB, Lester WS, Christian H, Shaw DA, Yuan J. *J Org Chem*. 1998; 63:8558. Krow GR, Lin G, Moore KP, Thomas AMC, DeBrosse C, Ross CW III, Ramjit HG. *Org Lett*. 2004; 6:1669. [PubMed: 15128263] Krow GR, Lin G, Yu F, Sonnet PE. *Org Lett*. 2003; 5:2739. [PubMed: 12868903]
11. Amii H, Ichihara Y, Nakagawa T, Kobayashi T, Uneyama K. *J Chem Soc, Chem Commun*. 2003:2902.
12. (a) Krow GR, Lin G, Herzon SB, Thomas AM, Moore KP, Huang Q, Carroll PJ. *J Org Chem*. 2003; 68:7562. [PubMed: 12968923] (b) Kwak YS, Winkler JD. *J Am Chem Soc*. 2001; 123:7429. [PubMed: 11472177]
13. (a) Wiberg KB, Lowry BR, Colby TH. *J Amer Chem Soc*. 1961; 83:3998. (b) McDonald RN, Reineke CE. *J Org Chem*. 1967; 32:1878. (c) Wiberg KB, Fenoglio R. *Tetrahedron Lett*. 1963; 4:1273.
14. (a) Malpass JR, White R. *J Org Chem*. 2004; 69:5328. [PubMed: 15287778] (b) Malpass JR, Handa S, White R. *Org Lett*. 2005; 7:2759. [PubMed: 15957940]
15. We did not expect to isolate aziridinium ion salts. Aziridinium salts are preferred for 6-anti-bromo-2-azabicyclo[2.2.1]heptanes, although not the 7-anti-isomers. See reference 14a and: Sosonyuk SE, Bulanov MN, Leshcheva IF, Zyk NV. *Russ Chem Bull*. 2002; 51:1254. Bulanov MN, Sosonyuk SE, Zyk NV, Zefirov NS. *Russ J Org Chem*. 2003; 39:415.
16. Krow GR, Herzon SB, Lin G, Qiu F, Sonnet PE. *Org Lett*. 2002; 4:3151. [PubMed: 12201739]
17. Shellhamer DF, Horney MJ, Pettus BJ, Pettus TL, Stringer JM, Heasley VL. *J Org Chem*. 1999; 64:1094.
18. Sakagami H, Ogasawara K. *Synlett*. 2001; 1:45.
19. Downie IM, Earle MJ, Heaney H, Shuhaibar KF. *Tetrahedron*. 1993; 49:4015.
20. (a) Creary X, Burtch EA, Jiang Z. *J Org Chem*. 2003; 68:1117. [PubMed: 12558442] (b) Creary X, Burtch EA. *J Org Chem*. 2004; 69:1227. [PubMed: 14961675]
21. Krow GR, Gandla D, Guo W, Centafont Lin G, DeBrosse C, Sonnet PE, Ross CW III, Ramjit H, Cannon KC. *J Org Chem*. 2008; 73:2122. [PubMed: 18290657]
22. Frisch, MJ.; Trucks, GW.; Schlegel, HB.; Scuseria, GE.; Robb, MA.; Cheeseman, JR.; Montgomery, JA., Jr; Vreven, T.; Kudin, KN.; Burant, JC.; Millam, JM.; Iyengar, SS.; Tomasi, J.; Barone, V.; Mennucci, B.; Cossi, M.; Scalmani, G.; Rega, N.; Petersson, GA.; Nakatsuji, H.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Klene, M.; Li, X.; Knox, JE.; Hratchian, HP.; Cross, JB.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, RE.; Yazyev, O.; Austin, AJ.; Cammi, R.; Pomelli, C.; Ochterski, JW.; Ayala, PY.; Morokuma, K.; Voth, GA.; Salvador, P.; Dannenberg, JJ.; Zakrzewski, VG.; Dapprich, S.; Daniels, AD.; Strain, MC.; Farkas, O.; Malick, DK.; Rabuck, AD.; Raghavachari, K.; Foresman, JB.; Ortiz, JV.; Cui, Q.; Baboul, AG.; Clifford, S.; Cioslowski, J.; Stefanov, BB.; Liu, G.; Liashenko, A.; Piskorz, P.; Komaromi, I.; Martin, RL.; Fox, DJ.; Keith, T.; Al-Laham, MA.; Peng, CY.; Nanayakkara, A.; Challacombe, M.; Gill, PMW.; Johnson, B.;

- Chen, W.; Wong, MW.; Gonzalez, C.; Pople, JA. Gaussian 03, Revision C.02. Gaussian, Inc; Wallingford CT: 2004.
23. Weinhold F. Schleyer, PvR; Allinger, NL.; Clark, T.; Gasteiger, J.; Kollman, PA.; Shaefer, HF., III; Schreiner, PR. Natural Bond Orbital Methods. Encyclopedia of Computational Chemistry. John Wiley & Sons Chichester, UK 1998; 3:1792. Glendening ED, Badenhoop JK, Reed AE, Carpenter JE, Bohmann JA, Morales CM, Weinhold F. NBO 5.0. 2001 Weinhold F, Landis CR. Valency and Bonding: A Natural Bond Orbital Donor–Acceptor Perspective. Cambridge University Press Cambridge, UK 2005. Depictions of orbital overlap were generated using NBOview 1.1: Wendt M, Weinhold F. NBOView 1.1. Theoretical Chemistry Institute, University of Wisconsin, Madison Madison, WI 2001
24. Crystals of dibromide **9** were subjected to x-ray analysis (see supplemental material). It was envisioned that an especially significant and equal interaction of the nitrogen lone pair electrons with the C-Br σ^* orbitals might lead at the extreme to a symmetrical structure for dibromide **9** with a planar nitrogen atom. However, nitrogen is tetrahedral and the sum of the bond angles including the nitrogen atom is 330.1°. The C-Br bond proximal to the *N*-benzyl group is 1.945 Å, and the distal C-Br bond is 1.942 Å. While suggestive of an $n \rightarrow \sigma^*$ interaction for the longer proximal bond distance, these bond lengths are essentially identical within experimental error (0.002 Å).
25. McWeeny R, Dierksen G. J Chem Phys. 1968; 49:4852.
26. (a) Becke AD. Phys Rev A. 1988; 38:3098. [PubMed: 9900728] (b) Lee C, Yang W, Parr RG. Phys Rev B. 1988; 37:785.
27. Independently, the aziridinium ions **41a-b** were drawn and their geometries were optimized using both methods (1) and (2). The aziridinium ions **41a-b** were calculated to be 42–46 kcal/mol less stable than the corresponding iminium ions. See the supplemental for details.
28. Dijkstra G, Kruizinga WH, Kellog RM. J Org Chem. 1987; 52:4230–4234.
29. (a) Salvatore RN, Nagle AS, Schmidt SE, Jung KW. Org Lett. 1999; 1:1893. (b) Salvatore RN, Nagle AS, Jung KW. J Org Chem. 2002; 67:674. [PubMed: 11856006]
30. Shukla R, Kida T, Smith BD. Org Lett. 2000; 2:3099. [PubMed: 11009355]

Figure 1.
400 MHz ^1H -NMR Pattern for H_5/H_6 Protons in Difluoride 18 (CDCl_3).

Figure 2.
 $n \rightarrow \sigma^*$ Orbital Overlaps for C-Br Bonds in Benzyl Dibromide 9.

SCHEME 1.
Synthesis of *N*-Benzylbromides.

SCHEME 2.
Reactions of dibromide 9.

SCHEME 3.
Reactions of Monobromides 10.

SCHEME 4.
Reactions of Fluorobromide 11.

SCHEME 5.

Calculated Ionic Intermediates for Reactions of *N*-Methyl-azabicyclic Bromides 38–40.

Table 1

Nucleophilic Substitutions of Dibromide **9**.

entry	substrate	reagent	conditions	product	X	Y	yield (%)
1	9	CsOAc	DMF/60 °C/5d	16a	OAc	OAc ^a	40
				17	Br	OAc	42
2	9	AgF	DMF/50 °C/8h	19	-	-	72
3	9	NaN ₃	DMF/60 °C/8d	20	N ₃	N ₃	34
				21	Br	N ₃	49 ^b
4	9	CsOAc	DMSO/60 °C/5d	16a	OAc	OAc	89
5	9	NaOAc	DMSO/60 °C/5d	16a	OAc	OAc	14 ^c
				17	Br	OAc	59
6	9	NaF	DMSO/70 °C/5d	19	-	-	22 ^d
7	16b	BAST	CH ₂ Cl ₂ /25 °C/12h	18	F	F	24
				19	-	-	40
8	9	AgF	CH ₃ NO ₂ /50 °C/8h	18	F	F	52
				19	-	-	24
9	9	NaN ₃	DMSO/60 °C/2d	20	N ₃	N ₃	87
10	9	NaSPh	DMSO/60 °C/5h	22	SPh	SPh	37
				23	Br	SPh	29

^a Also 10% dibromide **9**.^b Also 17% of dibromide **9**.^c Also 15% dibromide **9**.^d Also 50% dibromide **9**.

Table 2

Nucleophilic Substitutions of Bromide **10**.

entry	substrate	reagent	conditions	product	X	yield (%)	
1	10	AgOAc	DMF/60 °C/12h	24a	OAc	54	
2	10	AgF	DMF/70 °C/24h	19	-	42 ^a	
3	10	NaF	DMF/70 °C/12h	10	Br	88	
4	10	NaN ₃	DMF/70 °C/12h	27	N ₃	51	
5	10	LiNu ^b	DMF/70 °C/8d	29	Nu ^b	55	
6	10	NaI ^c	DMF/70 °C/3d	31	I	50 ^d	
7	10	CsOAc ^e	DMSO/70 °C/6h	24a	OAc	90	
8	10	NaF	DMSO/70 °C/12h	10	Br	82	
9	24b	BAST	CH ₂ Cl ₂ /40 °C/12h	26	F	62	
10	10	AgF	CH ₃ NO ₂ /50 °C/12h	26	F	80	
11	10	NaN ₃	DMSO/70 °C/5h	27	N ₃	88	
12	10	NaSPh	DMSO/60 °C/5h	30	SPh	77	
13	10	NaI ^f	Acetone/reflux/4d	31	I	74 ^g	

^a Bromide **10** was stable in DMF/70 °C/12h; 90% recovery, no **19** formed.

^b Nu = N-imidazole.

^c 3 Equiv.

^d Admixed with unreacted bromide **10**.

^e To separate samples of the monobromide **10** in DMSO-d₆ there was added 1.5 equiv of either NaOAc (sample A) or CsOAc (sample B). After 6h the conversion to acetate **24a** was 39% for sample A and 66% for sample B by NMR analysis.

^f 20 equiv.

Table 3

Nucleophilic Substitutions of Bromofluoride **11**.

entry	substrate	reagent	conditions	product	X	yield (%)
1	11	CsOAc	DMF/70 °C/5d	32a	OAc	30 ^a
2	11	NaN ₃	DMF/70 °C/5d	34	N ₃	43 ^b
3	11	NaOAc	DMSO/70 °C/5d	32a	OAc	33 ^c
4	11	CsOAc	DMSO/70 °C/5d	32a	OAc	90
5	11	NaN ₃	DMSO/70 °C/7d	34	N ₃	67
6	11	NaSPh	DMSO/60 °C/5h	37	SPh	15 ^d
7	11	NaSPh	DMSO/60 °C/9d	37	SPh	69 ^e

^a Also 64% unreacted **11**.

^b Also 31% unreacted **11**.

^c Also 64% unreacted **11**.

^d Also 66% unreacted **11**.

^e Also 4% unreacted **11**.

Table 4

Second order perturbative estimates (NBO basis) for $n \rightarrow \sigma^*$ interaction energies for bromides 9–11.

entry	substrate	$n \rightarrow \sigma^*$ (kcal/mol) ^a		substrate	$n \rightarrow \sigma^*$ (kcal/mol)	
		X	N $\rightarrow$ C5-Br		N $\rightarrow$ C5-Br	N $\rightarrow$ C6-X
1	9 <i>endo</i> -N-Bn ^c	Br	1.71	9 <i>exo</i> -N-Bn	0.96	1.71
2	10 <i>endo</i> -N-Bn	H	1.75	10 <i>exo</i> -N-Bn	0.89	(0.55)
3	11 <i>endo</i> -N-Bn	F	1.63	11 <i>exo</i> -N-Bn	0.92	(1.63)

^aGeometry optimizations, frequency calculations, and NBO analyses were performed at the B3LYP/6-311+G(2d,p) level of theory on **9–11**.^{22,23}

^bThose bonds that do not have leaving groups for substitutions are in parentheses.

^cThe benzyl group has been arbitrarily assigned as *endo* (or *exo*) to enable us to distinguish the two bromides as C5 and C6 for purposes of this analysis.